Corticosteroid use in COVID-19 patients : a systematic review and meta-analysis on clinical outcomes
BACKGROUND: In the current SARS-CoV-2 pandemic, there has been worldwide debate on the use of corticosteroids in COVID-19. In the recent RECOVERY trial, evaluating the effect of dexamethasone, a reduced 28-day mortality in patients requiring oxygen therapy or mechanical ventilation was shown. Their results have led to considering amendments in guidelines or actually already recommending corticosteroids in COVID-19. However, the effectiveness and safety of corticosteroids still remain uncertain, and reliable data to further shed light on the benefit and harm are needed.
OBJECTIVES: The aim of this systematic review and meta-analysis was to evaluate the effectiveness and safety of corticosteroids in COVID-19.
METHODS: A systematic literature search of RCTS and observational studies on adult patients was performed across Medline/PubMed, Embase and Web of Science from December 1, 2019, until October 1, 2020, according to the PRISMA guidelines. Primary outcomes were short-term mortality and viral clearance (based on RT-PCR in respiratory specimens). Secondary outcomes were: need for mechanical ventilation, need for other oxygen therapy, length of hospital stay and secondary infections.
RESULTS: Forty-four studies were included, covering 20.197 patients. In twenty-two studies, the effect of corticosteroid use on mortality was quantified. The overall pooled estimate (observational studies and RCTs) showed a significant reduced mortality in the corticosteroid group (OR 0.72 (95%CI 0.57-0.87). Furthermore, viral clearance time ranged from 10 to 29 days in the corticosteroid group and from 8 to 24 days in the standard of care group. Fourteen studies reported a positive effect of corticosteroids on need for and duration of mechanical ventilation. A trend toward more infections and antibiotic use was present.
CONCLUSIONS: Our findings from both observational studies and RCTs confirm a beneficial effect of corticosteroids on short-term mortality and a reduction in need for mechanical ventilation. And although data in the studies were too sparse to draw any firm conclusions, there might be a signal of delayed viral clearance and an increase in secondary infections.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
---|---|
Enthalten in: |
Critical care (London, England) - 24(2020), 1 vom: 14. Dez., Seite 696 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
van Paassen, Judith [VerfasserIn] |
---|
Links: |
---|
Themen: |
Adrenal Cortex Hormones |
---|
Anmerkungen: |
Date Completed 31.12.2020 Date Revised 07.12.2022 published: Electronic Citation Status MEDLINE |
---|
doi: |
10.1186/s13054-020-03400-9 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM318828138 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM318828138 | ||
003 | DE-627 | ||
005 | 20231225170155.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1186/s13054-020-03400-9 |2 doi | |
028 | 5 | 2 | |a pubmed24n1062.xml |
035 | |a (DE-627)NLM318828138 | ||
035 | |a (NLM)33317589 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a van Paassen, Judith |e verfasserin |4 aut | |
245 | 1 | 0 | |a Corticosteroid use in COVID-19 patients |b a systematic review and meta-analysis on clinical outcomes |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 31.12.2020 | ||
500 | |a Date Revised 07.12.2022 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a BACKGROUND: In the current SARS-CoV-2 pandemic, there has been worldwide debate on the use of corticosteroids in COVID-19. In the recent RECOVERY trial, evaluating the effect of dexamethasone, a reduced 28-day mortality in patients requiring oxygen therapy or mechanical ventilation was shown. Their results have led to considering amendments in guidelines or actually already recommending corticosteroids in COVID-19. However, the effectiveness and safety of corticosteroids still remain uncertain, and reliable data to further shed light on the benefit and harm are needed | ||
520 | |a OBJECTIVES: The aim of this systematic review and meta-analysis was to evaluate the effectiveness and safety of corticosteroids in COVID-19 | ||
520 | |a METHODS: A systematic literature search of RCTS and observational studies on adult patients was performed across Medline/PubMed, Embase and Web of Science from December 1, 2019, until October 1, 2020, according to the PRISMA guidelines. Primary outcomes were short-term mortality and viral clearance (based on RT-PCR in respiratory specimens). Secondary outcomes were: need for mechanical ventilation, need for other oxygen therapy, length of hospital stay and secondary infections | ||
520 | |a RESULTS: Forty-four studies were included, covering 20.197 patients. In twenty-two studies, the effect of corticosteroid use on mortality was quantified. The overall pooled estimate (observational studies and RCTs) showed a significant reduced mortality in the corticosteroid group (OR 0.72 (95%CI 0.57-0.87). Furthermore, viral clearance time ranged from 10 to 29 days in the corticosteroid group and from 8 to 24 days in the standard of care group. Fourteen studies reported a positive effect of corticosteroids on need for and duration of mechanical ventilation. A trend toward more infections and antibiotic use was present | ||
520 | |a CONCLUSIONS: Our findings from both observational studies and RCTs confirm a beneficial effect of corticosteroids on short-term mortality and a reduction in need for mechanical ventilation. And although data in the studies were too sparse to draw any firm conclusions, there might be a signal of delayed viral clearance and an increase in secondary infections | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Meta-Analysis | |
650 | 4 | |a Systematic Review | |
650 | 4 | |a COVID-19 | |
650 | 4 | |a Coronavirus | |
650 | 4 | |a Corticosteroids | |
650 | 4 | |a Mechanical ventilation | |
650 | 4 | |a Mortality | |
650 | 4 | |a SARS-CoV-2 | |
650 | 4 | |a Viral clearance | |
650 | 7 | |a Adrenal Cortex Hormones |2 NLM | |
700 | 1 | |a Vos, Jeroen S |e verfasserin |4 aut | |
700 | 1 | |a Hoekstra, Eva M |e verfasserin |4 aut | |
700 | 1 | |a Neumann, Katinka M I |e verfasserin |4 aut | |
700 | 1 | |a Boot, Pauline C |e verfasserin |4 aut | |
700 | 1 | |a Arbous, Sesmu M |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Critical care (London, England) |d 1997 |g 24(2020), 1 vom: 14. Dez., Seite 696 |w (DE-627)NLM097399787 |x 1466-609X |7 nnns |
773 | 1 | 8 | |g volume:24 |g year:2020 |g number:1 |g day:14 |g month:12 |g pages:696 |
856 | 4 | 0 | |u http://dx.doi.org/10.1186/s13054-020-03400-9 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 24 |j 2020 |e 1 |b 14 |c 12 |h 696 |